POST-TEST

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Triple-Negative Breast Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase II SWOG-S1416 trial is inves- 4. Which of the following results was tigating cisplatin with or without veliparib demonstrated in the Phase Ib/II trial of for patients with metastatic triple-negative the combination of the antibody-drug breast cancer (TNBC) and/or BRCA conjugate ladiratuzumab vedotin with mutation-associated BC with or without as first-line therapy for brain metastases. Which of the following patients with advanced TNBC? results was demonstrated in this study? a. Promising activity with over 90% a. The addition of veliparib to cisplatin of patients achieving tumor reduc- showed no significant improvement tion regardless of PD-L1 expression in progression-free survival (PFS) in level BRCA-like advanced TNBC b. Promising activity only in patients b. The addition of veliparib to cisplatin with tumors expressing high levels significantly improved PFS in of PD-L1 BRCA-like advanced TNBC c. The combination was highly toxic c. The addition of veliparib to and elicited significantly low levels cisplatin significantly improved of activity with less than 5% of overall survival (OS) in BRCA-like patients achieving tumor reduction advanced TNBC d. The addition of veliparib to cisplatin 5. The ongoing Phase III KEYNOTE-522 showed no significant improve- trial is investigating pembrolizumab in ment in PFS or OS in BRCA-like combination with versus advanced TNBC chemotherapy alone as neoadjuvant therapy, followed by adjuvant pembro- 2. Which of the following Grade 3 or higher lizumab versus placebo after definitive adverse events is commonly observed surgery for patients with newly in patients with HER2-negative BC diagnosed Stage II or III TNBC. Which harboring BRCA1/2 mutations who are of the following results was demon- receiving single-agent therapy with either strated with respect to pathologic of the FDA-approved PARP inhibitors complete response (pCR) at the first olaparib or talazoparib? interim analysis in patients who received pembrolizumab and neoadjuvant chemo- a. Alopecia therapy versus those who received b. Diarrhea placebo and neoadjuvant chemotherapy? c. Headache a. Significantly higher rate of pCR d. Myelosuppression compared to those who received neoadjuvant chemotherapy alone 3. The Phase III ASCENT trial demon- b. No difference in pCR compared to strated a statistically significant improve- those who received neoadjuvant ment in PFS and OS in favor of the chemotherapy alone antibody-drug conjugate sacituzumab govitecan over treatment of physician’s c. Lower rate of pCR compared to choice for patients with metastatic those who received neoadjuvant TNBC in which line of treatment? chemotherapy alone a. First-line setting b. Second-line setting c. After 2 or more prior lines of chemotherapy d. First- or later-line setting

QID 3185 POST-TEST

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Triple-Negative Breast Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

6. Results from the Phase III IMpassion031 b. While steroids can be highly effec- trial of in combination with tive in managing irAEs, they signifi- neoadjuvant anthracycline/nab pacli- cantly diminish the efficacy of taxel-based chemotherapy compared to anti-PD-1/PD-L1 therapies chemotherapy alone for patients with c. After the resolution of irAEs, orally early-stage TNBC demonstrated which of or intravenously administered the following results? steroids should be immediately a. No improvement in pCR with the discontinued to rapidly increase the addition of atezolizumab efficacy of anti-PD-1/PD-L1 thera- b. Benefit in pCR with the addition pies of atezolizumab observed only in patients with PD-L1-postive TNBC 9. The primary results from the Phase III and not in those with PD-L1- IMpassion131 trial of paclitaxel with or negative disease without atezolizumab as first-line therapy c. A statistically significant increase for patients with locally advanced or in pCR with the addition of atezoli- metastatic TNBC were presented at the zumab, regardless of PD-L1 status 2020 ESMO virtual meeting by Miles and colleagues. Which of the following d. A greater benefit in pCR with the results was reported in patients with addition of atezolizumab in the PD-L1-positive disease? subgroup analysis of patients with a. The addition of atezolizumab to node-negative TNBC paclitaxel significantly improved 7. Which of the following statements best PFS only describes the timing of the onset of b. The addition of atezolizumab to toxicities commonly associated with the paclitaxel significantly improved OS use of immune checkpoint inhibitors only (ICIs) for patients with TNBC? c. The addition of atezolizumab to a. In most patients, rash occurs after paclitaxel significantly improved the patient has been on an ICI for both PFS and OS at least 6 months and never before d. No significant improvement was b. The timing of the onset of toxicities demonstrated in PFS or OS with such as rash, diarrhea, endocrinop- the addition of atezolizumab to athies or pneumonitis can be highly paclitaxel variable c. Immune-related adverse events 10. Which of the following AKT inhibitors associated with ICIs never occur has shown promising activity and is after treatment with the ICI has currently being investigated in a Phase been discontinued III trial for patients with TNBC? a. Trilaciclib 8. Which of the following is an important b. Veliparib strategy to note when managing the c. Capivasertib immune-related adverse events (irAEs) d. associated with the use of anti-PD-1/ e. Ceralasertib PD-L1 therapies? a. When steroids are intravenously administered, it is important to taper steroids over 4 to 6 weeks after toxicity resolves QID 3185